Regenxbio has a competitive advantage in the market with its proprietary NAV technology platform, based on AAV vectors, that is highly effective, efficient, and scalable. The recent Phase II trial on ...

SAN FRANCISCO--(BUSINESS WIRE)--Vector Capital (“Vector”), a leading private equity firm specializing in transformational investments in established technology businesses, today announced it has ...

MILWAUKEE, Jan. 8, 2026 /PRNewswire/ -- Vector Technologies, a leader in industrial and hydro excavation vacuum systems, proudly celebrates its 50th anniversary in 2026. Since its founding in 1976, ...

Demand for lentiviral vectors will continue to outstrip supply until the industry has access to more efficient, purpose-built manufacturing and bioprocessing technologies. The warning comes from ...

Based in San Francisco, Vector Capital invests in middle-market technology and technology-enabled businesses Vector was founded in 1997 Vector Capital has agreed to acquire San Francisco-based ...

The science of gene therapy is enjoying a renaissance after ups and downs over the past 25 years. The heart of this field still largely relies on viral vector gene transfer systems that have evolved ...